Clinical Trial Update: A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC

View source ↗

Summary

A clinical trial update suggests that combining AKR1B10 and CA19-9 improves the diagnosis of pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Pancreatic Ductal Adenocarcinoma | Status: COMPLETED